Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/300% above fair value
$2.05−0.04 (-1.91%)
Close on Nov 12, 2026Market cap $121.74MP/E 29.3Yield –
Foghorn Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Foghorn Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $77.66M, down 7.5% year over year. For fiscal 2025 it was $85.47M, down 9.6% from the year before. The highest annual figure on record is $109.69M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.47M | -9.6% |
| FY2024 | Dec 31, 2024 | $94.53M | -13.8% |
| FY2023 | Dec 31, 2023 | $109.69M | +3.9% |
| FY2022 | Dec 31, 2022 | $105.62M | +31.5% |
| FY2021 | Dec 31, 2021 | $80.33M | +39.2% |
| FY2020 | Dec 31, 2020 | $57.72M | +30.1% |
| FY2019 | Dec 31, 2019 | $44.36M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.84M | -5.8% |
| Q2 FY2026 | Jun 30, 2026 | $18.52M | -15.0% |
| Q1 FY2026 | Mar 31, 2026 | $18.26M | -15.6% |
| Q4 FY2025 | Dec 31, 2025 | $22.05M | +7.5% |
| Q3 FY2025 | Sep 30, 2025 | $20.00M | -19.0% |
| Q2 FY2025 | Jun 30, 2025 | $21.79M | -8.4% |
| Q1 FY2025 | Mar 31, 2025 | $21.63M | -15.3% |
| Q4 FY2024 | Dec 31, 2024 | $20.51M | -15.3% |
| Q3 FY2024 | Sep 30, 2024 | $24.69M | -6.0% |
| Q2 FY2024 | Jun 30, 2024 | $23.80M | -18.6% |
| Q1 FY2024 | Mar 31, 2024 | $25.53M | -14.8% |
| Q4 FY2023 | Dec 31, 2023 | $24.21M | -14.2% |
| Q3 FY2023 | Sep 30, 2023 | $26.25M | -2.5% |
| Q2 FY2023 | Jun 30, 2023 | $29.25M | +12.6% |
| Q1 FY2023 | Mar 31, 2023 | $29.99M | +22.3% |
| Q4 FY2022 | Dec 31, 2022 | $28.21M | +25.6% |
| Q3 FY2022 | Sep 30, 2022 | $26.93M | +31.4% |
| Q2 FY2022 | Jun 30, 2022 | $25.97M | +39.3% |
| Q1 FY2022 | Mar 31, 2022 | $24.51M | +30.9% |
| Q4 FY2021 | Dec 31, 2021 | $22.46M | +36.4% |
| Q3 FY2021 | Sep 30, 2021 | $20.49M | +27.2% |
| Q2 FY2021 | Jun 30, 2021 | $18.64M | +36.8% |
| Q1 FY2021 | Mar 31, 2021 | $18.73M | +62.8% |
| Q4 FY2020 | Dec 31, 2020 | $16.47M | +21.8% |
| Q3 FY2020 | Sep 30, 2020 | $16.11M | +42.7% |
| Q2 FY2020 | Jun 30, 2020 | $13.63M | – |
| Q1 FY2020 | Mar 31, 2020 | $11.50M | – |
| Q4 FY2019 | Dec 31, 2019 | $13.52M | – |
| Q3 FY2019 | Sep 30, 2019 | $11.29M | – |
See a number that looks wrong?